STOCK TITAN

China Pharma estimates Q3 net loss at about $1.90M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

China Pharma Holdings, Inc. (CPHI) said time constraints in compiling, disseminating and reviewing required information made timely filing of its Form 10-Q for the quarter ended September 30, 2026 impracticable without undue hardship and expense. It endeavors to file by November 23, 2026. Management estimates, subject to change upon completion of the financial statements, revenue of approximately $1.15 million, up from approximately $0.76 million a year earlier; operating loss of approximately $1.88 million, compared with approximately $0.63 million; net loss of approximately $1.90 million, compared with approximately $0.65 million; and comprehensive loss of approximately $1.49 million, compared with approximately $0.59 million.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointRevenue rose to approximately $1.15 million from approximately $0.76 million.

Negative

  • Moderate pointNet loss increased to approximately $1.90 million from approximately $0.65 million.
Revenue Approximately $1.15 million, compared with approximately $0.76 million Three months ended September 30, 2026, compared with the three months ended September 30, 2025; management estimates subject to change upon completion of the financial statements.
Loss from operations Approximately $1.88 million, compared with approximately $0.63 million Three months ended September 30, 2026, compared with the three months ended September 30, 2025; management estimates subject to change upon completion of the financial statements.
Net loss Approximately $1.90 million, compared with approximately $0.65 million Three months ended September 30, 2026, compared with the three months ended September 30, 2025; management estimates subject to change upon completion of the financial statements.
Comprehensive loss Approximately $1.49 million, compared with approximately $0.59 million Three months ended September 30, 2026, compared with the three months ended September 30, 2025; management estimates subject to change upon completion of the financial statements.
loss from operations financial
"loss from operations increased to approximately $1.88 million"
Loss from operations is the money a company loses from its main business activities, like selling products or services, before considering other expenses or income. It shows whether the company's core business is making or losing money. This figure matters because it helps investors understand if the business is running efficiently or struggling to earn enough to cover its costs.
comprehensive loss financial
"comprehensive loss increased to approximately $1.49 million"
Comprehensive loss measures the total decrease in a company’s value over a reporting period by combining its regular profit-or-loss with other gains or losses that don’t show up on the main income line—things like currency swings, changes in the value of certain investments, or pension adjustments. For investors it matters because it reveals hidden hits to a company’s equity that aren’t reflected in net income, offering a fuller picture of financial health, similar to checking both your bank balance and the value of investments when assessing your net worth.
Rule 12b-25 regulatory
"In accordance with Rule 12b-25 of the Securities Exchange Act of 1934"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CPHI’s estimated results for the quarter ended September 30, 2026?

Management estimated revenue at approximately $1.15 million, loss from operations at approximately $1.88 million, net loss at approximately $1.90 million, and comprehensive loss at approximately $1.49 million. The estimates remain subject to change upon completion of the financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: September 30, 2026

 

☐ Transition Report on Form 10-K

 

☐ Transition Report on Form 20-F

 

☐ Transition Report on Form 11-K

 

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: _____________________________________

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

  

PART I – REGISTRANT INFORMATION

 

China Pharma Holdings, Inc.

Full Name of Registrant:

 

N/A

Former Name if Applicable:

 

Second Floor, No. 17, Jinpan Road

Address of Principal Executive Office (Street and number):

 

Haikou, Hainan Province, China 570216

City, State and Zip Code

 

 

PART II – RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

 

  (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
       
☒  (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       
  (c)   The accountant’s statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

 

PART III – NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The compilation, dissemination and review of the information required to be presented in the quarterly report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Quarterly Report”) imposed time constraints that have rendered timely filing of the Quarterly Report impracticable without undue hardship and expense to the registrant. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the registrant endeavors to file its Quarterly Report no later than November 23, 2026.

 

PART IV – OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

Zhilin Li   +86-898   6681-1730
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

☒ Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☒ Yes ☐ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. 

 

Management estimates to have several material changes to the registrant’s results of operations, which are still subject to change upon the completion of the financial statements, including: (i) revenue increased to approximately $1.15 million for the three months ended September 30, 2026 from approximately $0.76 million for the three months ended September 30, 2025; (ii) loss from operations increased to approximately $1.88 million for the three months ended September 30, 2026 from approximately $0.63 million for the three months ended September 30, 2025; (iii) net loss increased to approximately $1.90 million for the three months ended September 30, 2026 from approximately $0.65 million for the three months ended September 30, 2025; and (iv) comprehensive loss increased to approximately $1.49 million for the three months ended September 30, 2026 from approximately $0.59 million for the three months ended September 30, 2025. Additional narrative and quantitative disclosure regarding the registrant’s results of operations for the three months ended September 30, 2026 will be disclosed in the registrant’s Quarterly Report on Form 10-Q.

 

2

  

  China Pharma Holdings, Inc.  
  (Name of Registrant as Specified in Charter)  

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 17, 2026 By: /s/ Zhilin Li
    Name: Zhilin Li
    Title: Chief Executive Officer
(Principal Executive Officer)

 

ATTENTION

 

Intentional misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).

 

3

 

Keep reading